Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.3 Reserve group antibiotics | No observations |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.3 Reserve group antibiotics | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. |
| List | Section | Observation |
|---|---|---|
| Cuba | 6.2.9 Otros antimicrobianos | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.3 Reserve group antibiotics | No observations |
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line |
Others observations: Procurement of this medicine through the Strategic Fund should be limited for use according to WHO recommended M/XDR-TB regimen in patients for whom there are few or no treatments available. Patients receiving this medicine should be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA). |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.3 Reserve group antibiotics | No observations |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line |
Others observations: Procurement of this medicine through the Strategic Fund should be limited for use according to WHO recommended M/XDR-TB regimen in patients for whom there are few or no treatments available. Patients receiving this medicine should be monitored for potential adverse events or related toxicities through national pharmacovigilance programs and data from the WHO Programme for International Drug Monitoring (UPPSALA). |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.2.5. Antituberculosis medicines |
This medicine requires a children care specialist. Others observations: Medicines for the treatment of multidrug-resistant tuberculosis (MDR-TB) should be used in specialized centres adhering to WHO standards for TB control. |
| PAHO Strategic Fund Medicine List | 2.4. Antiberculosis med. 2nd line | No observations |